MARKET

BPMC

BPMC

Blueprint Medicines Corp
NASDAQ
116.81
+1.84
+1.60%
Closed 17:08 07/22 EDT
OPEN
116.25
PREV CLOSE
114.97
HIGH
117.20
LOW
114.33
VOLUME
603.94K
TURNOVER
0
52 WEEK HIGH
121.90
52 WEEK LOW
43.89
MARKET CAP
7.31B
P/E (TTM)
-24.2249
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)
TipRanks · 1h ago
Weekly Report: what happened at BPMC last week (0715-0719)?
Weekly Report · 1d ago
Stifel Nicolaus Remains a Buy on Blueprint Medicines (BPMC)
TipRanks · 3d ago
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary. Small cap stocks are enduring their largest period of underperformance versus large caps to start a year in the last 51 years. Volatility in the Russell 2000 Growth Index was only down 2.9% in the second quarter of 2024.
Seeking Alpha · 5d ago
Blueprint Medicines: Overdue For A Breather
Seeking Alpha · 6d ago
Oppenheimer’s best SMID-cap ideas: AI, health, obesity drugs, and more
Oppenheimer’s best SMID-cap ideas: AI, health, obesity drugs, and more. The ideas exhibit a bullish technical trend. Analysts updated their best SMid-cap. Ideas for the year, providing exposure to high-growth themes, such as artificial intelligence.
Seeking Alpha · 07/15 18:00
Weekly Report: what happened at BPMC last week (0708-0712)?
Weekly Report · 07/15 09:25
Blueprint Medicines Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 07/12 17:27
More
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Webull offers Blueprint Medicines Corp stock information, including NASDAQ: BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.